FDA Brief

Warning letters Biologics

FDA warning letter to

ProDx Health

High riskIssued Feb 10Posted Feb 10Center for Biologics Evaluation and Research (CBER)

FDA warns ProDx Health that its HIV sample self-collection kits are sold without marketing authorization.

What happened

FDA reviewed ProDx Health's website in February 2026 and the firm's February 3, 2026 response to earlier FDA correspondence. FDA found the firm offers HIV serological diagnostic sample self-collection kits for delivery to individuals to self-collect samples and ship them to labs for HIV testing without FDA's approval for the device (a PMA) or approval to study it (an IDE). FDA also said the firm did not provide the required pre-sale notification to FDA (a 510(k)).

What FDA found

  1. The HIV sample self-collection kits are adulterated because they have no approved premarket approval application or approved investigational device exemption.

    FD&C Act section 501(f)(1)(B), 21 U.S.C. 351(f)(1)(B); section 515(a), 21 U.S.C. 360e(a); section 520(g), 21 U.S.C. 360j(g)
  2. The kits are misbranded because ProDx Health did not notify FDA before introducing the device into commercial distribution.

    FD&C Act section 502(o), 21 U.S.C. 352(o); section 510(k), 21 U.S.C. 360(k)

What FDA wants

FDA asks ProDx Health to immediately stop any activities that cause the kits to be misbranded or adulterated. Within 15 working days of receipt, the firm must write to FDA with the steps taken to correct the violations, prevent recurrence, and related documentation; if it cannot finish, it must explain the delay and give a completion date.

Who should pay attention

  • makers of at-home sample collection kits
  • HIV test developers and labs receiving self-collected samples
  • companies selling diagnostic devices without FDA marketing authorization

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. AseptiKits, LLC

    AseptiKits marketed unapproved sterile-preparation device kits without FDA clearance or approval, FDA says.

    High risk
  2. Happiest Baby, Inc.

    FDA says Happiest Baby marketed unapproved SNOO sleep sacks and hospital bundle and mishandled complaints.

    High risk
  3. Estar Technologies Ltd

    FDA warns Estar Technologies over selling seven unapproved PRP/PRF device kits in the U.S. without clearance or approval.

    High risk
  4. Genetrace

    FDA warned Genetrace that its HIV dried blood spot self-collection kit is unapproved and misbranded.

    High risk